HRP20192241T1 - Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe - Google Patents

Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe Download PDF

Info

Publication number
HRP20192241T1
HRP20192241T1 HRP20192241TT HRP20192241T HRP20192241T1 HR P20192241 T1 HRP20192241 T1 HR P20192241T1 HR P20192241T T HRP20192241T T HR P20192241TT HR P20192241 T HRP20192241 T HR P20192241T HR P20192241 T1 HRP20192241 T1 HR P20192241T1
Authority
HR
Croatia
Prior art keywords
ndv
promoter
preparation
antigen
locus
Prior art date
Application number
HRP20192241TT
Other languages
English (en)
Croatian (hr)
Inventor
Michel Bublot
Teshome Mebatsion
Joyce Pritchard
Perry LINZ
Original Assignee
Boehringer Ingelheim Animal Health USA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192241(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Animal Health USA Inc. filed Critical Boehringer Ingelheim Animal Health USA Inc.
Publication of HRP20192241T1 publication Critical patent/HRP20192241T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/125—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HRP20192241TT 2011-11-30 2012-11-29 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe HRP20192241T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564877P 2011-11-30 2011-11-30
US201261694957P 2012-08-30 2012-08-30
PCT/US2012/067135 WO2013082327A1 (en) 2011-11-30 2012-11-29 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
EP12801680.5A EP2785373B1 (en) 2011-11-30 2012-11-29 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Publications (1)

Publication Number Publication Date
HRP20192241T1 true HRP20192241T1 (hr) 2020-03-06

Family

ID=47358292

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20190525TT HRP20190525T8 (hr) 2011-11-30 2012-11-29 Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
HRP20192241TT HRP20192241T1 (hr) 2011-11-30 2012-11-29 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe
HRP20192215TT HRP20192215T1 (hr) 2011-11-30 2019-12-10 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20190525TT HRP20190525T8 (hr) 2011-11-30 2012-11-29 Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20192215TT HRP20192215T1 (hr) 2011-11-30 2019-12-10 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe

Country Status (29)

Country Link
EP (7) EP2785373B1 (enExample)
JP (1) JP6149301B2 (enExample)
KR (1) KR102013135B1 (enExample)
CN (3) CN104159604B (enExample)
AR (2) AR090401A1 (enExample)
BR (1) BR112014013276B1 (enExample)
CA (1) CA2857025C (enExample)
CO (1) CO7061033A2 (enExample)
CY (3) CY1121528T1 (enExample)
DK (3) DK3251691T3 (enExample)
ES (3) ES2775218T3 (enExample)
HK (1) HK1248566A1 (enExample)
HR (3) HRP20190525T8 (enExample)
HU (3) HUE047909T2 (enExample)
IN (1) IN2014CN04833A (enExample)
LT (3) LT2785373T (enExample)
ME (1) ME03433B (enExample)
MX (2) MX365984B (enExample)
PE (1) PE20141482A1 (enExample)
PH (2) PH12014501174B1 (enExample)
PL (3) PL3251691T3 (enExample)
PT (3) PT3251691T (enExample)
RS (3) RS58610B1 (enExample)
RU (1) RU2620936C2 (enExample)
SI (3) SI2785373T1 (enExample)
SM (3) SMT201900690T1 (enExample)
UA (1) UA118651C2 (enExample)
WO (2) WO2013082327A1 (enExample)
ZA (1) ZA201403804B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932604B2 (en) 2011-10-21 2015-01-13 Intervet Inc. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CN104159604B (zh) 2011-11-30 2016-08-24 梅里亚有限公司 表达禽类病原体的抗原的重组hvt载体及其用途
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
AR103245A1 (es) * 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
HK1257191A1 (zh) 2015-08-10 2019-10-18 The Texas A&M University System 重组火鸡疱疹病毒疫苗及其用途
HUE061405T2 (hu) 2016-06-17 2023-06-28 Intervet Int Bv Nem patogén Marek-betegség vírus konstruktok, amelyek fertõzõ laryngotracheitis vírus és fertõzõ bursitis vírus antigéneket kódolnak
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
MA55772A (fr) * 2016-12-14 2022-03-02 Boehringer Ingelheim Animal Health Usa Inc Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant
CN106929483B (zh) * 2017-01-19 2020-09-25 北京邦卓生物科技有限公司 表达鸡新城疫病毒f基因的重组火鸡疱疹病毒的构建及其应用
CN106701693A (zh) * 2017-01-19 2017-05-24 北京邦卓生物科技有限公司 表达血清ⅰ型马立克氏病病毒gb基因的重组火鸡疱疹病毒的构建及其应用
EP3391903B1 (en) * 2017-04-21 2022-02-23 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN107603958A (zh) * 2017-09-29 2018-01-19 天津农学院 融合表达TM‑1基因和gD基因重组腺病毒的构建方法及重组腺病毒和应用
JP7721269B2 (ja) * 2017-10-12 2025-08-12 インターベット インターナショナル ベー． フェー． 複数の異種抗原をコードする組換え非病原性マレック病ウイルス構築物
WO2019121888A1 (en) 2017-12-20 2019-06-27 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
CN108543067A (zh) * 2017-12-25 2018-09-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 共表达h5亚型禽流感ha蛋白和传染性法氏囊vp2蛋白的重组火鸡疱疹病毒疫苗株
US20210046130A1 (en) * 2018-01-24 2021-02-18 Virogin Biotech Canada Ltd Recombinant viral vaccines
CN109468315B (zh) * 2018-12-07 2021-09-07 袁隆平农业高科技股份有限公司 水稻耐淹基因Sub1共显性分子标记及应用
BR112021012032A2 (pt) 2018-12-21 2021-11-16 Ceva Sante Animale Herpesvírus aviários recombinantes contendo múltiplos genes estranhos
AU2020347180A1 (en) * 2019-09-11 2022-03-24 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
CN110872578B (zh) * 2019-11-29 2022-09-16 扬州优邦生物药品有限公司 一株变异株传染性法氏囊病毒、亚单位疫苗及其制备方法和应用
EP4076516A1 (en) * 2019-12-20 2022-10-26 Intervet International B.V. Multivalent hvt vector vaccine
US11299517B2 (en) * 2020-04-15 2022-04-12 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against Marek's disease and Newcastle disease
EP4378474A3 (en) 2020-06-17 2024-08-28 Boehringer Ingelheim Vetmedica GmbH Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
CN112206317B (zh) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 一种草鱼出血病二价核酸菌蜕疫苗的制备方法
PE20231916A1 (es) 2020-10-15 2023-11-28 Ceva Sante Animale Hvt recombinante y usos de este
CN114317827B (zh) * 2022-01-07 2023-03-24 河南省农业科学院 一种鉴别不同血清型马立克病病毒感染与免疫的多重pcr引物、方法及应用
CN115927213A (zh) * 2022-09-30 2023-04-07 扬州大学 表达鸡新城疫病毒f基因的重组火鸡疱疹病毒及其构建方法和应用
CN116139264A (zh) * 2022-12-28 2023-05-23 中国农业科学院上海兽医研究所 重组火鸡疱疹病毒活载体疫苗及其应用
JP2024112294A (ja) * 2023-02-07 2024-08-20 株式会社微生物化学研究所 ワクチン
KR102758680B1 (ko) * 2023-07-10 2025-02-04 (주)바이오드 전염성 f낭병 및/또는 조류 인플루엔자 항원을 발현하는 키메라 바이러스 및 이를 포함하는 백신 조성물
KR102758682B1 (ko) * 2024-01-02 2025-02-04 (주)바이오드 전염성 f낭병 항원을 발현하는 키메라 바이러스 및 이를 포함하는 백신 조성물
US12473572B1 (en) 2024-06-28 2025-11-18 Farmacológicos Veterinarios S.A.C. Gallid alphaherpesvirus 3 (MDV-2), a viral vector against different avian pathogens: a new vaccination strategy in the poultry industry

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
JP2779447B2 (ja) 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
BE1004877A3 (fr) 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2719056B1 (fr) 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
CA2626498C (en) * 1994-08-09 2011-04-12 Schering-Plough Limited Recombinant chimeric virus
RU2059414C1 (ru) * 1994-12-09 1996-05-10 Государственная Курская биофабрика - Фирма "БИОК" Поливалентная вакцина для профилактики болезни марека и способ ее изготовления
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH104956A (ja) * 1996-06-21 1998-01-13 Univ Michigan State マレク病ワクチン製造のための維持可能な細胞株の改良
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
CA2268825C (en) 1996-10-11 2006-04-18 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
EP1026246B1 (en) * 1997-10-03 2006-11-29 Zeon Corporation Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
KR100354972B1 (ko) * 2000-04-11 2002-10-05 대한민국 닭전염성기관지염 바이러스 ｓ1 단백질을 발현하는유전자재조합 마렉바이러스 및 그의 제조방법
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) * 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
CN105567648B (zh) * 2009-04-15 2019-09-03 法国诗华大药厂 用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗
CN104159604B (zh) 2011-11-30 2016-08-24 梅里亚有限公司 表达禽类病原体的抗原的重组hvt载体及其用途

Also Published As

Publication number Publication date
HUE047724T2 (hu) 2020-05-28
ES2719409T3 (es) 2019-07-10
RS59892B1 (sr) 2020-03-31
KR20140097515A (ko) 2014-08-06
EP2785374B2 (en) 2022-08-17
CY1122872T1 (el) 2021-05-05
EP2785373A1 (en) 2014-10-08
WO2013082327A1 (en) 2013-06-06
DK2785374T3 (en) 2019-04-08
HK1200018A1 (en) 2015-07-31
HRP20192215T1 (hr) 2020-02-21
HRP20190525T4 (hr) 2023-01-20
ES2719409T5 (es) 2022-12-07
JP6149301B2 (ja) 2017-06-21
PH12015502790B1 (en) 2019-03-13
PL2785374T3 (pl) 2019-07-31
SI2785373T1 (sl) 2020-02-28
EP2785373B1 (en) 2019-11-20
SI3251691T1 (sl) 2020-02-28
LT3251691T (lt) 2020-02-10
JP2015500806A (ja) 2015-01-08
IN2014CN04833A (enExample) 2015-09-18
EP3251691B1 (en) 2019-11-20
HUE047909T2 (hu) 2020-05-28
ZA201403804B (en) 2015-04-29
PL2785374T5 (pl) 2023-01-09
SMT201900188T1 (it) 2019-05-10
RS59893B1 (sr) 2020-03-31
SMT201900671T1 (it) 2020-01-14
PL2785373T3 (pl) 2020-06-01
BR112014013276A2 (pt) 2018-05-15
EP3263130A1 (en) 2018-01-03
PH12015502790A1 (en) 2017-07-10
CN104159604B (zh) 2016-08-24
BR112014013276B1 (pt) 2021-07-27
RU2014126375A (ru) 2016-01-27
CY1121528T1 (el) 2020-05-29
CA2857025C (en) 2021-08-03
EP2785374A2 (en) 2014-10-08
MX2014006360A (es) 2015-03-05
MX361893B (es) 2018-12-18
ES2785045T3 (es) 2020-10-05
PH12014501174A1 (en) 2014-09-08
WO2013082317A8 (en) 2014-07-10
RS58610B1 (sr) 2019-05-31
ES2775218T3 (es) 2020-07-24
CN105920598A (zh) 2016-09-07
RU2620936C2 (ru) 2017-05-30
AR090401A1 (es) 2014-11-12
EP4112073A1 (en) 2023-01-04
PT2785373T (pt) 2020-01-27
SMT201900690T1 (it) 2020-01-14
KR102013135B1 (ko) 2019-08-22
MX2014006361A (es) 2015-03-05
CN104159604A (zh) 2014-11-19
HUE042471T2 (hu) 2019-07-29
EP2785374B1 (en) 2019-01-09
WO2013082327A8 (en) 2014-07-03
DK2785373T3 (da) 2020-02-03
UA118651C2 (uk) 2019-02-25
HRP20190525T8 (hr) 2023-01-20
AR089039A1 (es) 2014-07-23
EP3251691A1 (en) 2017-12-06
ME03433B (me) 2020-01-20
LT2785373T (lt) 2020-02-10
DK3251691T3 (da) 2020-02-10
CN104159605B (zh) 2019-04-19
HK1247832A1 (en) 2018-10-05
HK1197175A1 (en) 2015-01-09
LT2785374T (lt) 2019-04-25
PT3251691T (pt) 2020-01-28
SI2785374T1 (sl) 2019-04-30
CY1124618T1 (el) 2022-03-24
EP3572092A1 (en) 2019-11-27
WO2013082317A3 (en) 2013-08-15
EP3578199A1 (en) 2019-12-11
HRP20190525T1 (hr) 2019-05-03
CA2857025A1 (en) 2013-06-06
CO7061033A2 (es) 2014-09-19
MX365984B (es) 2019-06-21
PT2785374T (pt) 2019-05-09
PE20141482A1 (es) 2014-11-08
HK1248566A1 (en) 2018-10-19
CN104159605A (zh) 2014-11-19
PH12014501174B1 (en) 2014-09-08
PL3251691T3 (pl) 2020-06-01
WO2013082317A2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
HRP20192241T1 (hr) Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe
Hein et al. Review of poultry recombinant vector vaccines
Müller et al. Current status of vaccines against infectious bursal disease
HRP20221527T1 (hr) Rekombinantni hvt vektori koji eksprimiraju mnoge antigene ptičjih patogena, i cjepiva koja ih sadrže
Mahgoub An overview of infectious bursal disease
Müller et al. Research on infectious bursal disease—the past, the present and the future
CA2868132C (en) Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
JP2015500806A5 (enExample)
RU2019115277A (ru) Рекомбинантные векторы, экспрессирующие антигены вируса птичьего гриппа, и их применения
PL197722B1 (pl) cDNA ptasiego paramiksowirusa, RNA, sposób wytwarzania infekcyjnej kopii ptasiego paramiksowirusa, infekcyjna kopia ptasiego paramiksowirusa, szczepionka, sposób rozróżniania zwierząt i zestaw diagnostyczny
Cui et al. Avirulent Marek’s disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine
CN110536697A (zh) 编码异源禽病原体抗原的重组3型禽疱疹病毒疫苗
RU2014120471A (ru) Конструкции рекомбинантного непатогенного вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса болезни ньюкасла
RU2016112951A (ru) Рекомбинанатные вирусы болезни марека и их применение
Ge et al. Novel in-ovo chimeric recombinant Newcastle disease vaccine protects against both Newcastle disease and infectious bursal disease
Yang et al. Recombinant infectious bronchitis virus (IBV) H120 vaccine strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against IBV and NDV challenge
CN104031889A (zh) 表达传染性法氏囊病毒vp2蛋白的重组火鸡疱疹病毒疫苗及应用
AU2023258457B2 (en) Live-attenuated flaviruses with heterologous antigens
Guo et al. Recombinant infectious hematopoietic necrosis virus expressing infectious pancreatic necrosis virus VP2 protein induces immunity against both pathogens
JP2009203242A5 (enExample)
Zhang et al. A novel inactivated bivalent vaccine for chickens against emerging hepatitis-hydropericardium syndrome and infectious bursal disease
Zhang et al. Transcriptional activity comparison of different sites in recombinant Marek's disease virus for the expression of the H9N2 avian influenza virus hemagglutinin gene
Lokhandwala et al. Priming cross-protective bovine viral diarrhea virus-specific immunity using live-vectored mosaic antigens
Guo et al. Multiantigen epitope fusion recombinant proteins from capsids of serotype 4 fowl adenovirus induce chicken immunity against avian Angara disease
JPH07503843A (ja) マレック病ウイルス組換えポックスウイルスワクチン